- In early August 2026, Waters Corporation reported second-quarter results showing sales of US$1.65 billion versus US$771 million a year earlier, alongside a shift from net income of US$147 million to a net loss of US$136 million, and issued third-quarter and full-year 2026 revenue guidance of US$1.75–1.76 billion and US$6.42–6.48 billion respectively.
- Management highlighted 9% organic constant currency growth, strong performance in pharmaceutical and academic markets, faster growth in newly acquired Biosciences and Diagnostic Solutions businesses, and launched the Xevo TQ Absolute XR IVD System to strengthen its clinical diagnostics offering.
- We will now examine how Waters’ raised full-year guidance and integration progress for its acquired businesses influence the existing investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Waters Investment Narrative Recap
To own Waters today, you need to believe the enlarged company can turn strong top-line momentum and the BD assets into durable, profitable growth while managing integration risk. The Q2 beat and slightly higher 2026 revenue guidance support the near term catalyst around synergy delivery, but the continued GAAP losses underline that execution on costs and margins is still the biggest near term risk rather than a resolved issue.
The launch of the Xevo TQ Absolute XR IVD System is especially relevant here, because it directly supports Waters’ push into clinical diagnostics where BD’s Diagnostic Solutions assets sit. This product broadens the IVD offering that management cites as growing faster than the legacy business, tying the nearer term revenue catalyst to the longer term question of whether Waters can defend pricing power and differentiation as competition intensifies in higher value testing workflows.
Yet, behind the stronger guidance, investors should also be aware of how integration risks around the BD businesses could still...
Read the full narrative on Waters (it's free!)
Waters' narrative projects $7.8 billion revenue and $1.3 billion earnings by 2029. This requires 27.3% yearly revenue growth and an earnings increase of about $850 million from $449.6 million today.
Uncover how Waters' forecasts yield a $413.26 fair value, a 3% upside to its current price.
Exploring Other Perspectives
The lowest ranked analysts paint a much more cautious picture, emphasizing that if integration of BD’s diagnostics lags, the forecast US$7.9 billion in 2029 revenue and US$1.1 billion in earnings might prove too optimistic. They see these hurdles as more serious than the consensus does, which shows how differently you and other investors might weigh today’s upbeat Q2 numbers against longer term uncertainty.
Explore 3 other fair value estimates on Waters - why the stock might be worth as much as 33% more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Waters research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Waters research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Waters' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com